Buprenorphine in the Treatment of Osteoarthritis (OA) in the Elderly

Phase 4 Completed 219 enrolled Napp Pharmaceuticals Limited

RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective is to compare buprenorphine transdermal delivery system (BTDS) with standard- treatment in subjects with osteoarthritis (OA).

Timeline

Start: 2006-03
Primary completion: —
Completion: 2007-12

Outcome

Met primary endpoint

paper CONCLUSIONS: 7-day buprenorphine patches plus oral paracetamol were non-inferior to co-codamol tablets with respect to analgesic efficacy in older adults with OA pain in the hip/knee. PMID 21477658 ↗

Publications

Conaghan PG, O'Brien CM, Wilson M, Schofield JP. Transdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and/or knee: a randomised trial. Osteoarthritis Cartilage. 2011 Aug;19(8):930-8. doi: 10.1016/j.joca.2011.03.011. Epub 2011 Apr 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Acetaminophen	Small molecule	500 mg	Oral
Subject	Buprenorphine	Other / unclassified	5 mg	Other
Subject	Buprenorphine	Other / unclassified	10 mg	Other
Subject	Buprenorphine	Other / unclassified	20 mg	Other
Comparator	Codeine	Small molecule	8 mg	Oral
Comparator	Codeine	Small molecule	15 mg	Oral
Comparator	Codeine	Small molecule	30 mg	Oral